Dr. Margolin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
113 Hartwell St
Lexington, MA 02421
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1991 - 1994
- Graduate HospitalInternship, Internal Medicine, 1990 - 1991
- Perelman School of Medicine at the University of PennsylvaniaClass of 1990
Certifications & Licensure
- MA State Medical License 1994 - 2015
Publications & Presentations
PubMed
- 2 citationsEndocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies.Colin M Dayan, Beatriz Lecumberri, Ilaria Muller, Sashiananthan Ganesananthan, Samuel F Hunter
Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2023-01-03 - 11 citationsMismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose...Pejman Sehatpour, Daniel C. Javitt, Heloise M. De Baun, Marlene Carlson, Anna Beloborodova
Neuropsychopharmacology. 2021-10-20 - 33 citationsEfficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial:Alasdair Coles, Douglas L. Arnold, Ann D Bass, Aaron Boster, D Alastair S Compston
Therapeutic Advances in Neurological Disorders. 2021-04-23
Press Mentions
- Cerevance Initiates Phase 2 Trial of CVN424 for Parkinson’s DiseaseDecember 4th, 2019
- Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424April 30th, 2019
Grant Support
- B Cell Responses To SHIVNational Institute Of Allergy And Infectious Diseases1999–2003
- Cloning Hiv-1-Neutralizing Fabs From LN Tissue SectionsNational Institute Of Allergy And Infectious Diseases1999–2000
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: